D1 and D2 trials compared guselkumab vs placebo in patients with active PsA, with the major difference between the two being that only biologic-naïve patients were enrolled in the D2 trial. Today, we discuss three abstracts presented at ACR 2021 that expand on that work with an additional year of data.
All News
Article
Article
The RheumNow faculty have been glued to their monitors all day, watching video, and running down abstract presentations to find the best – several of these stood out as #ACRBests. Here is a listing of “Best” they saw on Day 1.
Article
The arsenal of therapeutics for psoriatic arthritis continues to increase. Risankizumab is an IL-23 inhibitor to the p19 subunit, currently being investigated for treatment of psoriatic arthritis.
Dr. Antoni Chan
Tweet
Guselkumab 100 mg Q4W and Q8W provided robust and sustained benefits to patients with active PsA across multiple domains. Listen to my interview with Prof. Laura Coates on this and other emerging treatments in PsA here https://t.co/PSbJ0HA5a6
@RheumNow #ACR21 Abstr#1335 https://t.co/WzBOYGOxAA
Pedro Castillo
Tweet
Supporting date for Ixekizumab in PsA with symptoms of axial involvement.
🔹Improvement in QoL (SF-36), ASDAS, BASDAI50
🔹Maintained at 52 weeks
🔹Stricter criteria (younger, ⬆️CRP) showed similar results
https://t.co/QSJLQTxLcW
#ACR21 Abst#3147
@RheumNow
Richard Conway
Tweet
Dr Oster presenting on IL-23 inhibitor Risankizumab in PsA. No surprises here, it works. We need comparative efficacy trials! Abstr#0453 #ACR21 @RheumNow https://t.co/mj8TeCqEcg
Risankizumab for Active Psoriatic Arthritis with Dr. Robert Chao ( @doctorRBC )
#ACR21
https://t.co/0zskkywWu1 https://t.co/n3qs19rQNG
Guselkumab treatment of PsA improved Hgb levels and ⬇️ incidence of anemia
⭐️Anemia resolution associated with improved clinical status
#ACR21
#ACRBest
Abs#1331
@RheumNow
https://t.co/nbG7DpMDaR https://t.co/rxWsVfNqed
Low incidence of GI-related serious AE in pooled 1 year data from VOY1&2 and DISC1&2 trials of Guselkumab for PsA/PsO treatment
⭐️no new onset IBD or exacerbation of IBD
⭐️no uveitis, infections, TB
Abs#1342
#ACR21
@RheumNow
https://t.co/x3OmLgInV0
SEC demonstrated significantly longer time to flare vs PBO w/ sustained improvement of ERA and JPsA signs and symptoms up to Wk 104. No new safety signals. Plenary Abs 1424 #ACR21 #RheumNow @RheumNow https://t.co/VF2HmJ3Ha9 https://t.co/ApYFusADHX
Abst1424 #ACR2021 @RheumNow study of SEC in children w/ERA or JPsA : 72% reduced flare risk. Improved JADAS-27 score in both the ERA and JPsA categories. ⬇️ disease activity, enthesitis count & joints with active arthritis. adverse events & serious AEs in the SEC & PBO comparable https://t.co/J4MdxeYxWZ
Richard Conway
Tweet
Guselkumab improves anaemia in PsA. Appears to correlate with CRP response, ie inflammatory effect. Anaemia resolution associated good outcomes, but many with good outcomes still anaemic. Abstr#1331 #ACR21 @RheumNow https://t.co/LL63Qc0nk5
Richard Conway
Tweet
Guselkumab (IL23p19 inhibitor) positive effect on axial outcomes in PsA, durable response across 2 years. Abstr#1330 #ACR21 @RheumNow https://t.co/8LOSdzCvRc
@JointMD shares his thoughts on IL23, IL17, TNF inh- where/when/how we might use them. @RheumNow #acr21 https://t.co/mVw05iFPhF
Risankizumab (IL-23i) KEEPsAKE 1 and 2 (phase 3) studies for PsA treatment
⬆️ACR20 response compared to pbo
⬆️secondary endpoints
⭐️no new safety signals
Abs#453
#ACR21 #ACRBest @RheumNow
https://t.co/7bwvIPMz38 https://t.co/TJaSqwipa5
Eric Dein
Tweet
#ACR21 Abst#0453. KEEPsAKE: Risankizumab (Skyrizi) monoclonal Ab inhibits IL23 by binding p19.
▶️150 mg RZB vs Placebo
⭐️RZB: higher ACR20/50/70, PASI90, HAQ-DI
⭐️Resolution of enthesitis, dactylitis. Improve fatigue, fxn
⭐️No safety signal
https://t.co/bqQJ4Zr7o5 @Rheumnow https://t.co/2ZfGRs2GUd
KEEPsAKE trial 1 (DMARD-IR) and 2 (DMARD/biologic-IR) on risankizumab (IL23i) for PsA:
👉phase 3 DBRPCT 24 weeks
👉150 mg week 0,4, 16 weeks
👉improved ACR20,ACR50,ACR70
👉improved PASI90
👉improved HAQ-DI
👉no increased safety signals
#ACR21 Abstr#0438 #Plenary @rheumnow https://t.co/ioIBXgV4Hi
sheila
Tweet
Promising results of Risankizumab for #psoriaticarthritis
🔸Pts significantly achieved higher rates of ACR20, 50 and 70 response at wk 24 vs. placebo
🔸Well tolerated and showed no safety signals
@RheumNow #ACR21 #ACRBest abs0453 https://t.co/TDSLEgF68g
Abst0453 #ACR21 @RheumNow integrated phase 2/3 trial results of il23 inhibitor Risankizumab (RZB) in PsA: significant improvement ACR20 at Week 24 (RZB 55.5% vs PBO 31.3%, P < 0.001), secondary endpoint met at HAQ DI, PASI, fatigue score& enthesitis. no new safety signals https://t.co/ZAVgswoXCf
